Tradestie Institutional Equity Comparison Engine
CING vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CING N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
ENTX
1Y +36.4% vs +11.6% ยท 52W Pos 18% vs 64%
Options & Structure Winner
ENTX
BREAKDOWN (16th %ile IV) vs CONSOLIDATION (32nd %ile IV)
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap
$62.5M
1M Return
+9.17%
1Y Return
+36.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
+0.17% 1D
Market Cap
$541.6M
1M Return
+2.89%
1Y Return
+11.62%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CING +36.39%
ENTX +11.62%
Spread: +24.77 pp (CING Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CING TTM Op. Margin: 0.0%
ENTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs ENTX. Trailing 12-month operating profitability (CING 0.0% vs ENTX 0.0%) and valuation multiples (CING N/M vs ENTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CING | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $62.5M | $541.6M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | CING |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -198.7% | -20.3% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 18% ($3โ$12) | 64% ($1โ$4) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 117% Vol | 1.07ฮฒ ยท 46% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 53.5 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CING vs ENTX Buy Guide
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
ENTX
CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CING nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.